

STEP THERAPY POLICY

- POLICY:** Ophthalmic Quinolone Antibiotics Step Therapy Policy
- Besivance (besifloxacin 0.6% ophthalmic suspension – Bausch + Lomb)
 - Ciloxan® (ciprofloxacin 0.3% ophthalmic ointment – Novartis)
 - Ciloxan® (ciprofloxacin 0.3% ophthalmic solution – Alcon, generic)
 - Levofloxacin 0.5% ophthalmic solution (generic only)
 - Moxeza® (moxifloxacin 0.5% ophthalmic solution – Alcon, generic)
 - Ocuflox® (ofloxacin 0.3% ophthalmic solution – Allergan, generic)
 - Vigamox® (moxifloxacin 0.5% ophthalmic solution – Novartis, generic)
 - Zymaxid® (gatifloxacin 0.5% ophthalmic solution – Allergan, generic)

REVIEW DATE: 10/25/2023

OVERVIEW

The ophthalmic fluoroquinolone products (besifloxacin, ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, and ofloxacin) are indicated for the treatment of **bacterial conjunctivitis** caused by susceptible strains of certain microorganisms.¹⁻⁸ Ciprofloxacin ophthalmic solution and levofloxacin ophthalmic solution are also indicated for the treatment of corneal ulcers caused by susceptible strains of certain microorganisms.^{2,7} The prescribing information for these products lists the specific strains.

Moxifloxacin ophthalmic solution 0.5% and Ciloxan ointment are preservative free.¹⁻⁸ The other ophthalmic products are preserved with benzalkonium chloride.¹⁻⁸

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

Automation: A patient with a of one Step 1 drug within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic ciprofloxacin 0.3% ophthalmic solution, generic gatifloxacin 0.5% ophthalmic solution, generic levofloxacin 0.5% ophthalmic solution, generic moxifloxacin hydrochloride 0.5% ophthalmic solution, generic ofloxacin 0.3% ophthalmic solution

Step 2: Besivance, Ciloxan ointment

CRITERIA

1. If the patient has tried one Step 1 Product, approve a Step 2 Product.
2. If the patient has already started treatment with Besivance or Ciloxan ointment, approve Besivance or Ciloxan ointment to complete the course of therapy.
3. No other exceptions are recommended.

10/25/2023

© 2023. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

REFERENCES

1. Ciloxan ointment [prescribing information]. East Hanover, NJ: Novartis; November 2019.
2. Ciloxan ophthalmic solution [prescribing information]. Fort Worth, TX: Alcon; April 2018.
3. Zymaxid ophthalmic solution [prescribing information]. Irvine, CA: Allergan; September 2016.
4. Moxeza ophthalmic solution [prescribing information]. Fort Worth, TX: Alcon; August 2023.
5. Vigamox ophthalmic solution [prescribing information]. East Hanover, NJ: Novartis; June 2020.
6. Ocuflox ophthalmic solution [prescribing information]. Irvine, CA: Allergan; April 2017.
7. Levofloxacin ophthalmic solution [prescribing information]. Lake Forest, IL: Akorn; February 2017.
8. Besivance [prescribing information]. Tampa, FL: Bausch + Lomb; February 2022.